Roche Holding (0QOK) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Roche Holding £316, price £324, upside -2.5%, quality 71 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Roche Holding for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
60‑month range £214.45 – £398.31 · fair‑value band £210.38 – £398.65 · the £323.90 price screens above the £315.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Show more
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Stock analysis
Roche Holding (0QOK) currently trades at £323.90, while our model-based Fair Value estimate is £315.85, so the stock looks roughly fairly valued today (gap 2.6%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £315.90 per share, and 5 of the 25 models we run sit above the £323.90 price.
Bear case: the Earnings-Based group reads lowest at £75.64, and 20 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: £210.38 (bear) to £398.65 (bull), the price of £323.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Roche Holding reported revenue of £62.8B in FY2021 versus £53.3B in FY2017, a compound +4.2%/yr. Reported net income was £13.9B in FY2021, compounding +12.7%/yr from FY2017.
Key figures
Market cap £301B · P/S ratio 4.78 · Dividend yield 2.5% · Net margin 22.2% · Return on equity 38.1% · Return on assets (EBIT) 19.6% · Operating margin 36.2% · Revenue (TTM) £63.0B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −2%, 0QOK screens richer than that median.
Fair Value models
Bear £210.38Fair Value £315.85Bull £398.65
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
’17
’18
’19
’20
’21
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
24.4% (2017) → 28.9% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score71 · Above median
Fair Value upside−2.5% · Above median
Profitability
Return on equity (TTM)38.1% · Top 25%
Return on assets13.5% · Top 25%
Net margin (TTM)19.6% · Top 25%
Operating margin (TTM)36.2% · Top 25%
Growth and dividend
Revenue growth−1.2% · Bottom 25%
Dividend yield (TTM)2.5% · Above median
Balance sheet
Debt / equity0.66× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Roche Holding Fair Value". https://www.fairvalue-calculator.com/stock/0QOK
Frequently asked questions
Is Roche Holding (0QOK) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of £315.85 versus a price of £323.90, about −2% upside (fairly valued).
What is the fair value of 0QOK?
Our model-based fair value for Roche Holding is £315.85 (as of Sep 28, 2026), built from audited fundamentals. The current price: £323.90.
What is the quality score of 0QOK?
Roche Holding has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Roche Holding (0QOK)?
Our model-based price target is the fair value of £315.85 (as of Sep 28, 2026) from 25 valuation models. Cautious scenario £210.38, optimistic scenario £398.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Roche Holding stock forecast for 2026?
Our models put fair value at £315.85, about −2% upside versus a price of £323.90 (fairly valued). Cautious scenario £210.38, optimistic scenario £398.65. The calculation is refreshed regularly with new filings.
What is the revenue of Roche Holding (0QOK)?
Roche Holding reported trailing-twelve-month revenue of about £63.0B (latest available figure, as of Sep 28, 2026).
Does Roche Holding pay a dividend?
Roche Holding currently shows a dividend yield of about 2.47% relative to its recent price (as of Sep 28, 2026).
What is the intrinsic value of Roche Holding (0QOK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Roche Holding it is £315.85 per share (as of Sep 28, 2026), against a price of £323.90. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Roche Holding stock overvalued or undervalued in 2026?
As of Sep 28, 2026, 0QOK trades above its calculated fair value: price £323.90, fair value £315.85, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QOK?
No. The price is what the market pays today (£323.90); the fair value is what the company's own numbers justify (£315.85). For Roche Holding the two are £8.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is Roche Holding worth?
The market values Roche Holding at about £301B (market capitalisation, as of Sep 28, 2026). Per share that is £323.90; our models calculate a fair value of £315.85 per share.
What do the bullish and bearish scenarios say about 0QOK?
Our models span a range for Roche Holding: cautious scenario £210.38, base £315.85, optimistic £398.65 per share (as of Sep 28, 2026, price £323.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Roche Holding (0QOK)?
Balance-sheet figures for Roche Holding (as of Sep 28, 2026): return on equity 38.1%, debt of 0.66 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is 0QOK from its 52-week high?
Roche Holding trades at £323.90, about 13% below its 52-week high of £373.77 and 25% above the low of £258.86 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £315.85 is for.
Which stocks are comparable to Roche Holding?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Merck & Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Roche Holding stock attractive at the current price?
The data as of Sep 28, 2026: price £323.90, calculated fair value £315.85 (−2%), Quality Score 71/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QOK calculated?
We run Roche Holding through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £315.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Roche Holding itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Roche Holding (0QOK)?
The closing price on Oct 2, 2026 was £323.90. Our model-based fair value is £315.85, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Roche Holding right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (£210.38 to £398.65) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Roche Holding
How large is the market capitalisation of Roche Holding (0QOK)?
The market capitalisation of Roche Holding is £301B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Roche Holding (0QOK)?
The price-to-sales ratio of Roche Holding is 4.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Roche Holding (0QOK)?
The dividend yield of Roche Holding is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Roche Holding (0QOK)?
The net margin of Roche Holding is 22.2% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Roche Holding (0QOK)?
The return on equity (ROE) of Roche Holding is 38.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Roche Holding (0QOK)?
On an EBIT basis the return on assets of Roche Holding is 19.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Roche Holding (0QOK)?
The operating margin of Roche Holding is 36.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Roche Holding (0QOK)?
Revenue at Roche Holding is growing −1.2% versus a year earlier (3y avg +3.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Roche Holding (0QOK)?
Earnings per share at Roche Holding are growing −7.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Roche Holding in the live analysis
One click puts Roche Holding on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
